SGALIHI@EC2704B

Morgan Stanley Cuts Alibab Health's Earnings Forecast and Maintains 'Reduce' Rating

Great Wall Securities Reaffirms Alibaba Health's Revenue Growth Target for FY2026 and Cuts Net Profit Growth Target

Alibaba's ATH Innovation Department's AI Model HappyHorse to Soon Open API

Goldman Sachs Downgrades Alibaba Health's Target Price to HKD 4.8

CLSA Downgrades Alibaba Health's Profit Forecast and Target Price

Alibaba Health and Novartis Announce Chronic Spontaneous Urticaria Digital Chronic Disease Collaboration

Alibaba CEO Wu Y 昺 Launches Enterprise AI-Native Work Platform “Wukong”

Alibaba Establishes Alibaba Token Hub to Advance AI Strategy

Alibaba DAMO Academy Develops Accurate Fatty Liver Screening AI Model

JD Health and Ali Health Strategic Divergence: JD Shifts to Heavy Asset Operations

Alibaba Health and Meiyuan Health Sign Strategic Cooperation Agreement

HSBC Raises Target Prices for JD Health and Alibaba Health

Alibaba Health Secures Systemic Licensing of People's Health Press Medical Publications

AliHealth's Medical AI Product Hydrogen Ion Reaches Content Collaboration with Chinese Medical Association

Alibaba Health's Hydrogen Ion Updates Precision Positioning Feature

Alibaba Health Pharmaceutical Chain Co., Ltd. Investigated for False Advertising

Alibaba Health Launches AI Product 'Hydroion'

Dain Biosea's Manlejing® Melatonin Granules Launched on Ali Health

Alibaba Health Partners with MeiLson for Pediatric Innovation Drug Cooperation

JPMorgan Increases Stake in Alibaba Health to 8.12%

MS GROUP HLDGS

REACH NEW HLDGS

HINSANG GROUP

NEW GONOW RV

XL2CSOPSMSN-U

XL2CSOPSMSN

YAN TAT GROUP

FUTONG TECH

NU ENVIRO

SMART-CORE

00241

M Stanley has downgraded ALI HEALTH's target price from HKD4.6 to HKD4.2 and maintained an Underweight rating. The firm expects revenue growth of 12%, 10%, and 9% for FY2026 to FY2028, but has reduced EPS forecasts by 13.8%, 14.7%, and 11.9% due to increased R&D expenses and lower gross margins. Adjusted net profit is projected to grow by 19%, 18%, and 18% during the same period. M Stanley believes ALI HEALTH's valuation is not favorable compared to peers given its moderate growth outlook.

AASTOCKS News

ALI HEALTH

Morgan Stanley

KINGWORLD

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M Stanley Cuts ALI HEALTH  TP to HKD4.2, Rating Underweight

S&P Global Market Intelligence has released data on the top 10 Hong Kong stocks with the highest short selling ratios as of April 24. Leading the list is CATLwith a short selling ratio of 35.425%, followed by ALI HEALTHat 35.397%. Other notable stocks include COSCO SHIP HOLDand JIANGSU EXPRESS. The report highlights significant short selling activity, indicating investor sentiment towards these stocks.

S&P Global Market Intelligence Lists Top 10 HK Stocks w/ Highest Short Selling Ratios as of Last Fri

BABA

09988

KBAB

BABX

BABO

- Britain is investigating the sale of health data from UK Biobank on China's Alibaba, which allegedly involves information from 500,000 individuals.  
- Science Minister Ian Murray stated that no personal identifiers were included in the data, and the government is collaborating with UK Biobank and Chinese authorities to remove the listings.  
- Access to the data has been paused while new technical measures are implemented, as the incident is viewed as a serious breach of data integrity.

Reuters

Alibaba

BABA-W

KraneShares 2x Long BABA Daily ETF

BABA 2x Long Daily ETF - GraniteShares

YieldMax BABA Option Income Strategy ETF

UK investigates after big health dataset listed for sale on China's Alibaba

688688

In Hangzhou, China, Alipay has introduced a new payment service utilizing AI Pay technology, allowing OpenClaw-type AI agents known as "lobsters" to conduct purchases and payments upon receiving user commands. These autonomous AI tools operate on behalf of users without the need for coding or intricate configurations. The service is equipped with multi-layer security measures for each transaction, enhancing the efficiency and capability of AI agents with Alipay.

Unusual Whales

ANT GROUP

BABA-WR

Alibaba HK SDR 5to1

Alipay AI Pay Launches New Service Enabling OpenClaw-type AI Agents to Make Payments

00772

KWEB

Lingxi Interactive, a subsidiary of Alibaba, is launching "Pipi Gu," an app integrating news, community features, and gacha mechanics, with its official WeChat account already live and a mini-program coming soon. Meanwhile, China Literature plans to release the "Yuegu Mi" mini-program by the end of 2024 and is developing a standalone app to establish a differentiated advantage in the fiercely competitive merchandise economy

Wallstreetcn

CHINA LIT

E Fund CSI HK Connect Internet ETF

Yinhua CSI Movies Theme ETF

Penghua CSI Media ETF

Hwabao CSI HK Equities Internet ETF

Krne Csi China Internet

AXA SPDB CSI Hugangshen Game and Culture Media ETF

ChinaAMC CSI Cultural Entertainment Media ETF

Alibaba Launches "Pipi Gu", China Literature Creates "Yuegu Mi" App: Tech Giants Battle for the Billion-Dollar Merchandise Sector

06618

562600

159929

510660

516610

589720

512010

Chinese tech giants Meituan, Alibaba, and JD.Com are competing in the AI healthcare market, launching various AI products this year. Meituan introduced the Xiaotuan Health Assistant for family health management, while JD Health upgraded its strategy to integrate AI into medical devices. Alibaba Health released Hydrogen Ion, an AI tool for doctors. Each company targets different user needs, with Meituan focusing on family health, JD on supply chain, and Alibaba on doctor assistance. The shift to AI in healthcare is driven by stagnating e-commerce traffic and the sector's high demand and repurchase rates.

- Chinese tech giants Meituan, Alibaba Group Holding, and JD.Com have heightened competition with their recent launches of AI service products in healthcare.  
- Meituan's AI assistant targets family health management, while JD Health integrates AI into medical devices, and Alibaba Health focuses on doctor support tools, catering to different user needs.  
- The drive into AI healthcare is driven by stagnating traditional e-commerce traffic, as firms seek to leverage high demand and user loyalty in the healthcare sector to establish competitive advantages.

SGALIHI@EC2704B(28211.HK)

M Stanley Cuts ALI HEALTH TP to HKD4.2, Rating Underweight

S&P Global Market Intelligence Lists Top 10 HK Stocks w/ Highest Short Selling Ratios as of Last Fri

UK investigates after big health dataset listed for sale on China's Alibaba

Alipay AI Pay Launches New Service Enabling OpenClaw-type AI Agents to Make Payments

Alibaba Launches "Pipi Gu", China Literature Creates "Yuegu Mi" App: Tech Giants Battle for the Billion-Dollar Merchandise Sector

China's Meituan, Alibaba, JD.Com Vie for AI in Healthcare Market